Oncotarget

Research Papers:

The attenuated hepatocellular carcinoma-specific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cells

Xin Wan, Ci Cheng, Zhe Lin, Runqiu Jiang, Wei Zhao, Xin Yan, Junwei Tang, Kun Yao, Beicheng Sun and Yun Chen _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:8822-8838. https://doi.org/10.18632/oncotarget.3558

Metrics: PDF 1083 views  |   HTML 1334 views  |   ?  


Abstract

Xin Wan1, Ci Cheng1, Zhe Lin1, Runqiu Jiang2, Wei Zhao1, Xin Yan1, Junwei Tang2, Kun Yao1, Beicheng Sun2 and Yun Chen1

1 Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, Jiangsu Province, China

2 Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China

Correspondence to:

Yun Chen, email:

Beicheng Sun, email:

Keywords: Lmdd-MPFG, Hepatocellular carcinoma, dendritic cells, PRRs

Received: December 21, 2014 Accepted: February 12, 2015 Published: March 12, 2015

Abstract

Immunotherapy is a promising treatment for liver cancer. Here, we tested the ability of the attenuated hepatocellular carcinoma-specific Listeria vaccine (Lmdd-MPFG) to treat hepatocellular carcinoma (HCC) in a mouse model. Immunization with the vaccine caused a strong anti-tumor response, especially in mice reinfused with dendritic cells (DCs). In mice that were also administered DCs, tumor suppression was accompanied by the strongest cytotoxic T lymphocyte response of all treatment groups and by induced differentiation of CD4+ T cells, especially Th17 cells. Additionally, the Lmdd-MPFG vaccine caused maturation of DCs in vitro. We demonstrated the synergistic effect of TLR4 and NLRP3 or NOD1 signaling pathways in LM-induced DC activation. These results suggest that the Lmdd-MPFG vaccine is a feasible strategy for preventing HCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3558